Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

This study is ongoing, but not recruiting participants.

Study NCT00138177 Information provided by Roswell Park Cancer Institute

First Received: August 29, 2005 Last Updated: March 8, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Publications:

Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res. 2009 May 1;15(9):3189-95. Epub 2009 Apr 21.

Fakih MG, Pendyala L, Smith P, et al.: A phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC). [Abstract] J Clin Oncol 25 (Suppl 18): A-4088, 185s, 2007.